Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Joshua Reed - Chief Financial Officer C.
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes plc (ALKS) M&A Call Transcript
Alkermes plc (NASDAQ:ALKS ) M&A Call October 22, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Joshua Reed - Chief Financial Officer Blair Jackson - Executive VP, Chief Risk Officer & COO Conference Call Participants Leonid Timashev - RBC Capital Markets, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division David Amsellem - Piper Sandler & Co., Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Anastasia Parafestas - Jefferies LLC, Research Division Jason Gerberry - BofA Securities, Research Division Douglas Tsao - H.C.
ALKS vs. RGEN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Alkermes (ALKS) or Repligen (RGEN). But which of these two stocks offers value investors a better bang for their buck right now?
Is Alkermes (ALKS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Alkermes: A More Than Solid Quarter
Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with progress around revenue growth from its product portfolio and some pipeline progress. Analyst commentary is positive, and Alkermes has a rock-solid balance sheet with over $1 billion in net cash and no long-term debt.
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.72 per share a year ago.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
